Shamonda Virus, Deep Dive: Virology, Vectors, Diagnostics

Educational information only. This guide explains published research and official health-agency statements about Shamonda virus. It is not medical advice, and it does not diagnose or recommend treatment for any individual. If you are unwell, or you care for livestock and are concerned about an animal, contact a qualified healthcare professional or a veterinarian and follow your country’s current guidance.

Read the companion guide: For the plain-language version — what Shamonda virus is, the first human case, symptoms and prevention — see the Tier 1 guide: Shamonda Virus: The First Human Case, Explained

Taxonomy and place in the Simbu serogroup

Shamonda virus (SHAV) is an enveloped, negative-sense RNA virus of the genus Orthobunyavirus, family Peribunyaviridae, within the Simbu serogroup. The serogroup is not a taxonomic rank but a serological cluster: its members are recognised by overlapping antibodies, which is why a blood test for one Simbu virus can cross-react with another, and why confirming a specific virus usually requires genetic testing rather than serology alone. The Simbu serogroup contains more than 25 viruses, most of them ruminant pathogens transmitted by biting midges.

Current taxonomy places Shamonda virus in the species Orthobunyavirus schmallenbergense — the same species that contains Schmallenberg virus. That placement is itself informative: it reflects how closely the two viruses are related at the genome level, and it is part of the reason their histories are entangled. Schmallenberg virus, discovered in Germany and the Netherlands in 2011, was initially described as a “Shamonda-like virus” because its small (S) genome segment showed about 97% identity with Shamonda virus. Full-genome analysis later resolved the relationship: Schmallenberg virus is a reassortant, carrying its medium (M) genome segment from Sathuperi virus and its S and large (L) segments from Shamonda virus. In other words, the virus that swept European livestock in 2011 was, in part, Shamonda virus reassembled with a different surface-protein segment — a precedent that matters when asking how the 2026 European Shamonda variants arose.

Shamonda virus was first isolated from cattle in Nigeria in 1965. From the early 2000s onwards it was identified in other regions of Africa and in Asia, including a documented resurgence in Japan. Until 2026, its known geography was therefore Africa and Asia, with Europe untouched. The 2026 European emergence changed that map in a single season, and the World Organisation for Animal Health (WOAH) reports two distinct variants behind the European outbreaks: SHAV-EU1 and SHAV-EU2. WOAH cautions that information on these variants is still evolving, that several aspects — epidemiology, full geographic distribution, pathogenicity, long-term impact and zoonotic potential — remain incompletely characterised, and that their precise characterisation and nomenclature are still being defined. Any account of the European variants that sounds settled is ahead of the evidence.

Genome architecture: three segments, six proteins

Like all orthobunyaviruses, Shamonda virus carries its genome as three separate segments of single-stranded, negative-sense RNA, named by size. The architecture is compact — the whole virion is built from just four structural proteins — but the segmented design has outsized consequences.

The L segment is the most conserved and is the usual target for phylogenetic analysis; the M segment, encoding the surface glycoproteins, carries the antigenic determinants that define serological relationships and is the segment most relevant to immunity and cross-protection; the S segment, encoding the nucleocapsid protein, is the target of the specific RT-PCR assay WOAH lists for Shamonda diagnosis.

Segmentation is what makes reassortment possible. When two related orthobunyaviruses infect the same cell — the same midge, or the same animal — their progeny can package segments from both parents, producing a virus with, for example, one parent’s surface proteins and the other’s polymerase. Schmallenberg virus is the textbook case: a natural reassortant of Shamonda-like and Sathuperi-like parents. Reassortment is also one of the mechanisms scientists are examining for the European Shamonda variants, but it is a hypothesis under investigation, not an established explanation for SHAV-EU1 or SHAV-EU2. A second natural Shamonda–Sathuperi reassortant was reported from Yonaguni Island, Japan, in 2025, with S and L segments almost identical to Japanese Shamonda isolates and an M segment very similar to Japanese Sathuperi isolates — evidence that this segment-swapping is an ongoing, natural process in this virus group, not a one-off event from 2011.

Vector ecology: the midge bottleneck

Transmission of Shamonda virus is understood to occur through bites from Culicoides midges. The WHO adds a qualification that is often dropped in retellings: further studies are needed to understand which exact arthropod species are involved in transmission. Culicoides is a genus of more than a thousand species; competence — the ability to acquire, replicate and transmit a given virus — varies sharply between species, and the competent species for Shamonda virus in Europe have not been pinned down. That gap matters for control, because midge control that targets the wrong species, or the wrong breeding sites, wastes effort.

What is known is the seasonal logic. Simbu-group outbreaks tend to follow the seasonal patterns of midges, and WOAH notes that the behaviour of the European variants in immunologically naive cattle populations may differ from Shamonda’s behaviour in endemic countries, where much of the livestock population has prior exposure. European herds in 2026 were largely naive, which is one reason the virus spread so visibly and so fast. The WHO has also noted that transmissibility of midge-borne viruses generally declines during cooler months, as vector activity falls — a seasonal brake that applies to onward spread but does not remove the virus from the landscape. Overwintering mechanisms for Shamonda virus — how it survives the midge-free months — are not established; for related viruses, possibilities discussed in the literature include low-level vector activity, transplacental persistence, and reintroduction, but none is confirmed for Shamonda.

There is no evidence of direct animal-to-animal transmission through contact. The exception is vertical transmission: an infected pregnant animal can transmit the virus to the foetus, which is the route behind the congenital malformations that define Simbu-group disease in livestock. For the human case, the vector hypothesis and the vertical-transmission fact should not be conflated: the patient was not pregnant, and no human vertical transmission has been reported or suggested.

Animal disease: what the virus does to livestock

In adult ruminants, Shamonda infection is typically mild and transient: fever, diarrhoea and reduced milk production, resolving without specific treatment — and there is no specific treatment for animals either. The economically and biologically significant disease is reproductive. Infection during pregnancy can cause abortions, stillbirths and severe foetal malformations, including the arthrogryposis–hydranencephaly syndrome familiar from Schmallenberg and Akabane virus: fixed, rigid joints and underdevelopment or absence of the cerebral hemispheres in the newborn. WOAH notes that abortions and severe foetal malformations have been reported in some affected animals in the 2026 European outbreaks, but that the European variants’ full teratogenic effects currently remain unknown. That distinction — observed malformations versus characterised teratogenic potential — is important: the European variants have not yet been through a full gestation-window study, so which stages of pregnancy are vulnerable, and how severely, is still open.

Neurological disease is the less common, more puzzling manifestation. WOAH lists neurological signs as reported less commonly, and Santé publique France notes that Shamonda virus has been detected in the central nervous system of horses exhibiting neurological disorders, as well as in alpacas. In France in 2026, a horse in the Hérault department was among the confirmed animal detections. The equine neurological findings raise a question that connects directly to the human case: whether Shamonda virus has a neurotropic potential — an ability to invade the central nervous system — that is expressed when it reaches a susceptible host, whether horse or human. That is a research question, not a conclusion; a handful of equine detections and one human case do not establish a neurotropism profile.

The host range deserves precision. Cattle are the main hosts and the species in which the virus is most commonly reported. Sheep, goats, horses and alpacas have also been reported infected, and in France in 2026 the virus was detected in sheep in two departments (Oise and Aveyron). Whether wild ruminants act as reservoirs or dead-end hosts is unknown for Shamonda specifically, although related Simbu viruses circulate in wild as well as domestic ruminants.

Diagnostics and the serology problem

Because clinical signs are unspecific, laboratory diagnosis is necessary. WOAH’s diagnostic pathway for Shamonda virus in animals combines molecular and serological methods:

• Pan-Simbu PCR — a broad assay that detects Simbu-group viruses without identifying which one.
• Specific RT-PCR targeting the S segment — the confirmatory molecular test for Shamonda virus.
• Sequencing and multi-segment screening of the M and L segments — needed to characterise variants and detect reassortment, since a single segment can mislead (as the Schmallenberg story shows).
• Commercial real-time RT-PCR kits — available in Europe for the current outbreaks.
• Serum neutralisation tests — for antibody detection and, crucially, for differentiating Shamonda from other Simbu-group viruses, since simpler antibody tests cross-react within the serogroup.

Suitable sample types are EDTA blood, serum from animals in the acute phase of infection, and brain and spleen tissue from aborted foetuses. Timing matters: viraemia in Simbu infections is brief, so a negative PCR from a convalescent animal does not exclude infection, and serology is often the only retrospective evidence.

Human diagnostics are at an earlier stage. France’s National Reference Center for Arboviruses is working to improve biological diagnostic methods to detect the virus in humans, and full-genome sequencing of the patient’s virus, compared with circulating animal strains, is under way. That comparison is the single most informative investigation still pending: if the patient’s virus matches an animal strain circulating in eastern France, the midge-bite hypothesis gains strong support; if it diverges, other routes and sources come back into play. A second diagnostic challenge is serological: because Simbu viruses cross-react, any future human serosurvey — the tool that would answer whether silent human infections have occurred — will need neutralisation-based confirmation, not ELISA alone, to distinguish Shamonda from Schmallenberg and other relatives. No such human serosurvey for Shamonda has been published.

The human case, appraised

The facts established by primary sources are these. On 7 October 2026, French health authorities were notified of a Shamonda virus infection in a severely immunocompromised patient being treated for a serious neurological condition at the Hospices Civils de Lyon, who subsequently died. Initial investigations detected the virus in several biological samples, confirming infection. The case was announced publicly on 22 October 2026 by France’s health and agriculture ministries, with the WHO confirming it as the first documented human case globally and the ECDC stating that it was carefully monitoring the situation in contact with French authorities and European partners.

Causality should be graded, not asserted. The evidence for a link between the virus and the patient’s neurological deterioration is the ministries’ statement that the neurological complications observed before death were very likely linked to the infection, based on preliminary findings. The evidence against a settled conclusion is explicit: the ECDC states that investigations into whether the virus caused or contributed to the patient’s death are ongoing, and WOAH repeats that further investigations are required to understand if the virus caused or contributed to the death, how the patient became infected, and the public health implications. The correct summary is therefore a three-part statement: infection confirmed; neurological complications very likely linked on preliminary findings; contribution to death unproven.

The exposure assessment is similarly provisional. The leading hypothesis is infection via the bite of an infected Culicoides midge in eastern France, where the virus circulated among animals in spring and summer 2026. Santé publique France notes that other hypotheses continue to be explored — the patient’s environment, recent travel, and any possible exposure to animals or insect vectors — and that the assessment takes into account information reported by the patient’s contacts. Until the genomic comparison between the patient’s virus and animal strains is published, the route of infection should be described as hypothesised, not established.

Two common misreadings should be avoided. First, the case does not show that Shamonda virus is now a human pathogen in the general sense: one case in a severely immunocompromised patient, detected through in-depth investigation at a major hospital, is consistent with opportunistic infection in a vulnerable host, and French authorities explicitly attribute the detection to the exceptional nature of the patient’s condition. Second, the case does not show that the virus is spreading between people: no human-to-human transmission has been identified, and no health risk to the general population has been identified at this time, according to both Santé publique France and the French ministries.

Details deliberately not stated

Some details about the patient — reported age and sex, specific neurological symptoms, and which viral variant was found in the patient — have appeared in news reports but were not confirmed in the primary sources consulted for this guide, so they are not stated here. The primary sources describe a serious neurological condition and neurological complications, and confirm that sequencing is under way; they do not name the variant found in the patient.

Comparison: Shamonda and its Simbu relatives

The table’s most instructive row is the human-infection row. Before October 2026, the Simbu teratogenic viruses shared a clean record: no documented human infections, with the exception of Oropouche virus — a Simbu-serogroup orthobunyavirus of South America and the Caribbean that does infect humans widely, causes febrile illness and meningoencephalitis, and is also transmitted by Culicoides midges. Oropouche is the standing counterexample to any claim that Simbu viruses cannot infect humans, and it is the reason the Shamonda case, while exceptional, was not biologically implausible. What Shamonda’s case adds is a second data point: a teratogenic Simbu virus of livestock, previously considered non-transmissible to humans, detected in a human host. Whether that data point represents opportunistic infection confined to the severely immunocompromised, or the first recognised case of a wider phenomenon that surveillance has simply missed, is the question that human serosurveys and improved diagnostics will have to answer.

Prevention, control and the vaccine gap

There are currently no treatments or vaccines for Shamonda virus in humans (WHO), and no commercially available vaccines against Shamonda virus in animals (WOAH). That double gap shapes the response: it is surveillance and vector management, not pharmaceutical intervention.

WOAH’s recommended risk-reduction measures for animals are vector-focused: physical barriers such as fine mesh screens and double-door entry-exit systems, reducing or eliminating vector breeding sites, vector surveillance and control around buildings, use of insect repellents during animal transport, and transporting animals during periods of low vector activity. Further detail is cross-referenced to the bluetongue chapter of WOAH’s Terrestrial Animal Health Code. For people, no Shamonda-specific measures exist; general midge-bite avoidance — covering skin, repellent, avoiding peak midge activity — is the only personal precaution with any basis, and it should be presented as general advice, not as Shamonda-specific guidance.

The vaccine gap also frames a research question with practical stakes. Schmallenberg vaccines exist in Europe, and Akabane vaccines exist in Japan, so the platform problem is not insoluble. But WOAH’s report that Schmallenberg immunity offers little cross-protection against Shamonda means a Shamonda vaccine cannot simply be assumed from a Schmallenberg one; it would need its own development and testing. Given the small animal-health market for a sporadic virus, and the absence of any demonstrated general-population human risk, commercial incentives for such a vaccine are weak — a familiar pattern for neglected arboviruses, and one reason public-sector reference laboratories, rather than manufacturers, are leading the current response.

WOAH also notes a governance detail that matters for how the story will be tracked: infection with Shamonda virus is not a WOAH-listed disease and is not formally recognised as an emerging disease under Article 1.1.4 of the Terrestrial Animal Health Code, so reporting is voluntary under Article 1.1.5. Surveillance data will therefore be patchier than for a listed disease, and absence of reports from a country will not reliably mean absence of the virus.

Research gaps and open questions

1. Causality in the human case. Completion of the investigations into whether the virus caused or contributed to the death, and publication of the clinical and pathological detail, is the single most important pending item.
2. Route and vector. Genomic comparison of the patient’s virus with animal strains; identification of the competent Culicoides species in Europe; and exclusion of non-vector routes.
3. Human susceptibility. Whether immunocompetent people can be infected, silently or symptomatically — answerable only by serosurveys using neutralisation-confirmed assays in exposed populations (farmers, veterinarians, residents of affected areas), modelled on the Schmallenberg serosurveys that found no infection.
4. Human disease spectrum. Incubation period, symptom profile, severity range, and whether neurological involvement is characteristic or an artefact of a single immunocompromised case — all unknown, with n = 1.
5. European variant biology. Full characterisation of SHAV-EU1 and SHAV-EU2: virulence, teratogenic window, host range, and whether reassortment contributed to their emergence.
6. Overwintering and persistence. How the virus survives between midge seasons, and whether it will become endemic in European livestock or fade as naive herds acquire immunity.
7. Cross-protection and vaccines. Quantification of the reported low cross-protection from Schmallenberg immunity, and whether a Shamonda-specific vaccine is warranted or feasible.
8. Surveillance design. Whether human surveillance should be added to animal surveillance in affected regions, and what diagnostic capacity (PCR, sequencing, neutralisation serology) reference laboratories need to detect a second case quickly.

The bottom line for experts

Shamonda virus is a Simbu-serogroup orthobunyavirus whose sixty-year history as an animal-only pathogen ended in October 2026 with a single, exceptional human case in a severely immunocompromised patient in Lyon. The virology is well understood at the genus level — tripartite genome, midge vector, reassortment-prone — and poorly understood at the level that now matters most: the European variants, the competent vectors, the human disease spectrum, and the causal role of the virus in the one death attributed, provisionally, to it. The comparison with Schmallenberg and Akabane cuts both ways: it explains why the case was surprising (neither relative has infected a human), and why it was not impossible (Oropouche, a fellow Simbu virus, infects humans widely). Until serosurveys, genomic comparisons and a second case — or a sustained absence of one — clarify the picture, the responsible expert position is the one the authorities have taken: exceptional case, no identified general-population risk, investigations ongoing, and every confident-sounding claim about Shamonda virus in humans marked as what it is — provisional.

Sources

1. World Health Organization. “Shamonda virus” — Questions and Answers. https://www.who.int/news-room/questions-and-answers/item/shamonda-virus
2. Santé publique France. “Shamonda Virus: First Human Case Detected in France — What Do We Know?” https://www.santepubliquefrance.fr/en/news/shamonda-virus-first-human-case-detected-france-what-do-we-know
3. World Organisation for Animal Health (WOAH). “Shamonda virus” disease page and FAQ, last updated 21 October 2026. https://www.woah.org/en/disease/shamonda-virus/
4. French Ministry of Health and Ministry of Agriculture joint statement, 22 October 2026, as reported by Reuters (22 October 2026) and the European Centre for Disease Prevention and Control statement of the same date.
5. Elliott RM. “Orthobunyaviruses: recent genetic and structural insights.” Nature Reviews Microbiology 12(10):673–685, 2014. https://doi.org/10.1038/nrmicro3332
6. Hoffmann B, Scheuch M, Höper D, et al. “Novel orthobunyavirus in cattle, Europe, 2011.” Emerging Infectious Diseases 18(3):469–472, 2012. https://doi.org/10.3201/eid1803.111905
7. Yanase T, Kato T, Aizawa M, et al. “Genetic reassortment between Sathuperi and Shamonda viruses of the genus Orthobunyavirus in nature: implications for their genetic relationship to Schmallenberg virus.” Archives of Virology 157(8):1611–1616, 2012. https://doi.org/10.1007/s00705-012-1341-8
8. Yanase T, Maeda K, Kato T, et al. “The resurgence of Shamonda virus, an African Simbu group virus of the genus Orthobunyavirus, in Japan.” Archives of Virology 150(2):361–369, 2005. https://doi.org/10.1007/s00705-004-0419-3
9. Goller KV, Höper D, Schirrmeier H, Mettenleiter TC, Beer M. “Schmallenberg virus as possible ancestor of Shamonda virus.” Emerging Infectious Diseases 18(10):1644–1646, 2012. https://doi.org/10.3201/eid1810.120835
10. Tomochi H, Mekaru Y, Murota K, et al. “Emergence of a natural reassortant between Shamonda and Sathuperi viruses of the species Orthobunyavirus schmallenbergense in Japan.” Archives of Virology 170, 2025. https://doi.org/10.1007/s00705-025-06233-5
11. Elbers ARW, Loeffen WLA, Quak S, et al. “Seroprevalence of Schmallenberg virus antibodies among dairy cattle, the Netherlands, winter 2011–2012.” Emerging Infectious Diseases 18(7), 2012. https://wwwnc.cdc.gov/eid/article/18/7/12-0323_article (Simbu serogroup background; Schmallenberg serosurveys in exposed farmers and veterinarians in Germany and the Netherlands found no infection; ECDC 2012 assessment that human transmission was unlikely but could not be ruled out).
12. “The Changing Landscape of Akabane Virus: A Comprehensive Review.” Viruses 18:770, 2026. https://doi.org/10.3390/v18070770 (no epidemiological or virological evidence of human infection with Akabane virus; zoonotic potential considered very low; Culicoides vectors including C. oxystoma and C. imicola).
13. Merck Veterinary Manual. “Akabane and Related Simbu Serogroup Virus Infections in Ruminants.” https://www.merckvetmanual.com/generalized-conditions/congenital-and-inherited-anomalies/akabane-and-related-simbu-serogroup-virus-infections-in-ruminants (vaccines against Akabane available in Japan, Schmallenberg vaccines produced in Europe; Simbu teratogenic orthobunyavirus infections in humans not recorded apart from Oropouche virus).
14. “Revisiting the Importance of Orthobunyaviruses for Animal Health: A Scoping Review of Livestock Disease, Diagnostic Tests, and Surveillance Strategies for the Simbu Serogroup.” Preprints.org, 2024. https://www.preprints.org/manuscript/202401.0717 (scoping-review context on Simbu diagnostic stages and test types; preprint — findings should be treated as non-peer-reviewed).